Cadila gets DCGI nod to conduct phase III trials for two-dose Covid vaccine
Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.05-10-2021
05-10-2021
Cadila Healthcare Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 201805-10-2021
Cadila Healthcare Ltd - 532321 - Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news article https://economictimes.indiatimes.com/ October 03, 2021 titled "Zydus Cadila gets permission to conduct phase III trial for two-dose Covid vaccine".Cadila Healthcare Ltd response is enclosed.05-10-2021
CADILA HEALTHCARE LTD. - 532321 - Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article https://economictimes.indiatimes.com/ October 03, 2021 titled "Zydus Cadila gets permission to conduct phase III trial for two-dose Covid vaccine".The reply is awaited.04-10-2021
Temasek to invest Rs 540 cr in True North-backed healthcare firm Integrace
Integrace is an orthopaedic and gynaecology-focused formulation player ranking among the top five in its area. It manages 20 brands and recently acquired two brands in Women's Health from Zydus Cadila04-10-2021
Centre hopeful of positive outcome from final talks with Zydus Cadila: Karnataka health minister
At the meeting, Sudhakar urged Mandaviya for the Centre's support to upgrade 250 primary health centres (PHCs) in Karnataka under the National Health Mission (NHM)04-10-2021
Cadila's outlook hinges on US sales revival, vaccine scale-up
The company's domestic sales grew by 63% year-on-year during Q1, driven by covid-related drugs28-09-2021
DCGI allows Serum to enrol 7-11 year olds in Covid vaccine trial
So far, only drugmaker Zydus Cadila's DNA Covid vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above28-09-2021
Zydus Cadila inks deal with Shipa Medicare for ZyCoV-D COVID-19 vaccine production
Shilpa Medicare Limited will produce the ZyCoV-D COVID-19 vaccine at its biologics R&D and manufacturing centre in Dharwad, Karnataka24-09-2021
Zydus Cadila unit gets USFDA nod for generic plaque psoriasis treatment drug
The company's US-based subsidiary Zydus Pharmaceuticals (USA) Inc has received final approval from the US Food and Drug Administration (USFDA) to market Apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg in the US market, Zydus Cadila said in a statement.24-09-2021